Tags

Type your tag names separated by a space and hit enter

A Feline-Specific Anti-Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease-Associated Pain: A Pilot Proof of Concept Study.
J Vet Intern Med 2016; 30(4):1138-48JV

Abstract

BACKGROUND

Neutralizing antibodies against nerve growth factor (NGF) are analgesic in rodent models, naturally occurring degenerative joint disease (DJD) pain in dogs, and chronic pain in humans.

OBJECTIVES

To evaluate the efficacy of a fully felinized anti-NGF antibody (NV-02) for the treatment of DJD pain and mobility impairment in cats.

ANIMALS

Thirty-four client-owned cats with DJD-associated pain and mobility impairment.

METHODS

In a placebo-controlled, pilot, masked clinical study, cats were randomized to a single treatment with NV-02 (0.4 mg/kg SC [n = 11] or 0.8 mg/kg SC [n = 12]) or placebo (saline, SC [n = 11]). Activity was measured objectively. Additionally, owners completed clinical metrology instruments (client-specific outcome measures [CSOM] and feline musculoskeletal pain index [FMPI]) on days 0 (screening), 14 (baseline), 35, 56, and 77. A repeated-measures model was used to evaluate the objective activity data.

RESULTS

NV-02 significantly increased objectively measured activity overall (P = .017) and at 2 (P = .035), 3 (P = .007), 4 (P = .006), 5 (P = .007), and 6 (P = .017) weeks after treatment. CSOM scores (P = .035) and pain (P = .024) showed a significant effect of treatment 3 weeks after administration. In the treatment group, 83% of the owners correctly identified the treatment administered compared with 45% of owners in the placebo group (P = .013). No treatment-related adverse effects were identified.

CONCLUSIONS

These pilot data demonstrate a 6-week duration positive analgesic effect of this fully felinized anti-NGF antibody in cats suffering from DJD-associated pain.

Authors+Show Affiliations

Comparative Pain Research Program, NCSU College of Veterinary Medicine, Raleigh, NC. Comparative Medicine Institute, NCSU College of Veterinary Medicine, Raleigh, NC.Comparative Pain Research Program, NCSU College of Veterinary Medicine, Raleigh, NC.Department of Statistics, NC State University, Raleigh, NC.Comparative Pain Research Program, NCSU College of Veterinary Medicine, Raleigh, NC.Nexvet Australia Pty Ltd, Melbourne, VIC, Australia.Comparative Pain Research Program, NCSU College of Veterinary Medicine, Raleigh, NC. Comparative Medicine Institute, NCSU College of Veterinary Medicine, Raleigh, NC. Center for Pain Research and Innovation, UNC Dental School, Chapel Hill, NC.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

27334504

Citation

Gruen, M E., et al. "A Feline-Specific Anti-Nerve Growth Factor Antibody Improves Mobility in Cats With Degenerative Joint Disease-Associated Pain: a Pilot Proof of Concept Study." Journal of Veterinary Internal Medicine, vol. 30, no. 4, 2016, pp. 1138-48.
Gruen ME, Thomson AE, Griffith EH, et al. A Feline-Specific Anti-Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease-Associated Pain: A Pilot Proof of Concept Study. J Vet Intern Med. 2016;30(4):1138-48.
Gruen, M. E., Thomson, A. E., Griffith, E. H., Paradise, H., Gearing, D. P., & Lascelles, B. D. (2016). A Feline-Specific Anti-Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease-Associated Pain: A Pilot Proof of Concept Study. Journal of Veterinary Internal Medicine, 30(4), pp. 1138-48. doi:10.1111/jvim.13972.
Gruen ME, et al. A Feline-Specific Anti-Nerve Growth Factor Antibody Improves Mobility in Cats With Degenerative Joint Disease-Associated Pain: a Pilot Proof of Concept Study. J Vet Intern Med. 2016;30(4):1138-48. PubMed PMID: 27334504.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Feline-Specific Anti-Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease-Associated Pain: A Pilot Proof of Concept Study. AU - Gruen,M E, AU - Thomson,A E, AU - Griffith,E H, AU - Paradise,H, AU - Gearing,D P, AU - Lascelles,B D X, Y1 - 2016/06/22/ PY - 2016/02/01/received PY - 2016/04/05/revised PY - 2016/04/28/accepted PY - 2016/6/24/entrez PY - 2016/6/24/pubmed PY - 2017/5/31/medline KW - Client-specific outcome measures KW - Feline musculoskeletal pain index KW - Osteoarthritis SP - 1138 EP - 48 JF - Journal of veterinary internal medicine JO - J. Vet. Intern. Med. VL - 30 IS - 4 N2 - BACKGROUND: Neutralizing antibodies against nerve growth factor (NGF) are analgesic in rodent models, naturally occurring degenerative joint disease (DJD) pain in dogs, and chronic pain in humans. OBJECTIVES: To evaluate the efficacy of a fully felinized anti-NGF antibody (NV-02) for the treatment of DJD pain and mobility impairment in cats. ANIMALS: Thirty-four client-owned cats with DJD-associated pain and mobility impairment. METHODS: In a placebo-controlled, pilot, masked clinical study, cats were randomized to a single treatment with NV-02 (0.4 mg/kg SC [n = 11] or 0.8 mg/kg SC [n = 12]) or placebo (saline, SC [n = 11]). Activity was measured objectively. Additionally, owners completed clinical metrology instruments (client-specific outcome measures [CSOM] and feline musculoskeletal pain index [FMPI]) on days 0 (screening), 14 (baseline), 35, 56, and 77. A repeated-measures model was used to evaluate the objective activity data. RESULTS: NV-02 significantly increased objectively measured activity overall (P = .017) and at 2 (P = .035), 3 (P = .007), 4 (P = .006), 5 (P = .007), and 6 (P = .017) weeks after treatment. CSOM scores (P = .035) and pain (P = .024) showed a significant effect of treatment 3 weeks after administration. In the treatment group, 83% of the owners correctly identified the treatment administered compared with 45% of owners in the placebo group (P = .013). No treatment-related adverse effects were identified. CONCLUSIONS: These pilot data demonstrate a 6-week duration positive analgesic effect of this fully felinized anti-NGF antibody in cats suffering from DJD-associated pain. SN - 1939-1676 UR - https://www.unboundmedicine.com/medline/citation/27334504/A_Feline_Specific_Anti_Nerve_Growth_Factor_Antibody_Improves_Mobility_in_Cats_with_Degenerative_Joint_Disease_Associated_Pain:_A_Pilot_Proof_of_Concept_Study_ L2 - https://doi.org/10.1111/jvim.13972 DB - PRIME DP - Unbound Medicine ER -